萬東醫療(600055.SH):控股股東擬變更為美的集團 明日復牌
格隆匯2月2日丨萬東醫療(600055.SH)公佈,2021年2月2日,公司控股股東江蘇魚躍科技發展有限公司、公司實際控制人吳光明、股東俞熔分別與美的集團股份有限公司(以下簡稱“美的集團”)簽署了《股份轉讓協議》,約定美的集團受讓公司合計1.57億股無限售流通股股份,佔公司股本的29.09%。
本次交易完成之後,公司的控股股東及實際控制人均將發生變更。本次交易之後,美的集團將控制公司29.09%的表決權,成為公司控股股東,何享健將成為公司的實際控制人。
公司股票將於2021年2月3日(週三)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.